Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 1889Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 680Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 567Stomach Neoplasms 523Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 404Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

Oxaliplatin 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Borderline Resectable Pancreatic Cancer × Clear all
NCT06387810 2024-07-10

undetermined

Peking Union Medical College Hospital

Phase 2 Recruiting
45 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡